1. Home
  2. MITQ vs JAGX Comparison

MITQ vs JAGX Comparison

Compare MITQ & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moving iMage Technologies Inc.

MITQ

Moving iMage Technologies Inc.

HOLD

Current Price

$0.58

Market Cap

5.9M

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$6.86

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MITQ
JAGX
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
5.0M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
MITQ
JAGX
Price
$0.58
$6.86
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
481.0K
511.9K
Earning Date
05-15-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.42
EPS
0.01
N/A
Revenue
$20,139,000.00
$11,511,000.00
Revenue This Year
N/A
$61.58
Revenue Next Year
N/A
N/A
P/E Ratio
$63.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$0.22
52 Week High
$1.66
$12.84

Technical Indicators

Market Signals
Indicator
MITQ
JAGX
Relative Strength Index (RSI) 46.41 93.91
Support Level $0.49 $1.77
Resistance Level $0.64 N/A
Average True Range (ATR) 0.08 0.20
MACD 0.00 0.65
Stochastic Oscillator 21.45 84.33

Price Performance

Historical Comparison
MITQ
JAGX

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: